Growth investors often find themselves torn between chasing high-flying names with sky-high valuations and settling for slower-moving, but cheaper, stocks. The "Affordable Growth" strategy aims to straddle that line, seeking out companies that deliver strong earnings and revenue expansion while still trading at reasonable, not excessive, prices. This approach, sometimes called Growth at a Reasonable Price (GARP), uses a disciplined checklist: a minimum growth rating, decent profitability and financial health scores, and a valuation rating that confirms the stock isn't overheated. The goal is to capture the upside of a growing business without paying a premium that could weigh on future returns.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics, with approved products like AMVUTTRA and ONPATTRO for rare diseases. When screened through the Affordable Growth lens, ALNY presents a strong case based on its fundamental report.
Growth Engine at Full Throttle
The most impressive aspect of ALNY’s profile is its growth trajectory. The company earns a ChartMill Growth rating of 8 out of 10, driven by explosive past and expected future performance. Over the last year, earnings per share (EPS) surged by an astounding 288.04% , while revenue grew by 82.57% . Looking ahead, analysts project an average annual EPS growth of 61.72% and revenue growth of 25.57% over the coming years. This kind of momentum is rare and forms the bedrock of any GARP strategy—the engine must be strong.
Valuation: The Reasonable Price Component
For a company growing at such a rapid clip, the valuation metrics are surprisingly grounded. The ChartMill Valuation rating comes in at 6 out of 10, which is notably above the threshold for affordable growth. While the trailing Price/Earnings (P/E) ratio of 79.59 looks elevated on its own, context is crucial. Compared to its Biotechnology industry peers, ALNY is actually cheaper than 90.63% of them based on the P/E ratio. More importantly, the Price/Forward Earnings ratio drops to a far more palatable 28.04, and the Enterprise Value to EBITDA ratio shows ALNY is cheaper than 90.82% of its industry. These multiples are significantly more reasonable when factoring in the strong growth, and the low PEG Ratio explicitly confirms that the price is compensating for the expected expansion. This is the core of the Affordable Growth thesis: paying a fair price for a high-growth business.
Profitability and Health: The Supporting Pillars
An affordable growth stock should not be a ticking time bomb. The strategy requires decent profitability and financial health to ensure the growth is sustainable. Alnylam scores a 6 on Profitability and a 5 on Health, both of which meet the screen’s criteria.
- Profitability: ALNY has turned profitable in the past year, with a net profit margin of 13.46% and an operating margin of 17.54% . Its Return on Equity (ROE) is a stellar 53.68% , outperforming nearly 98% of its industry peers. This demonstrates the business is converting revenue into bottom-line earnings effectively.
- Health: The company’s balance sheet shows some mixed signals. On the positive side, the Altman-Z score is a strong 6.40, indicating a very low bankruptcy risk, and the current ratio of 3.13 shows ample short-term liquidity. However, a Debt/Equity ratio of 2.31 is on the higher side, reflecting some reliance on external financing. This is a point to monitor, but the overall health rating remains acceptable for the strategy.
Analyst and Strategy Alignment
Putting it all together, the fundamental report available here summarizes ALNY as having "excellent growth while it is valued at reasonable prices." It notes the stock as "very considerable for growth investing." This aligns perfectly with the Affordable Growth screen’s objective. The strong growth provides upside potential, while the reasonable valuation relative to its industry and future earnings helps reduce the risk of overpaying. The decent profitability and health ratings provide a floor, suggesting the business is stable enough to support its expansion plans.
Investors looking to find similar candidates that combine strong growth with fair valuations can explore the full list of results from the screen. For more opportunities, check out the Affordable Growth stock screener results to see how other stocks compare.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance and projections are not guarantees of future results.
Read full article here »
View the Zacks #1 Rank List
Alnylam Pharmaceuticals (NASDAQ:ALNY): An Affordable Growth Stock with Explosive Momentum and a Reasonable Price
Growth investors often find themselves torn between chasing high-flying names with sky-high valuations and settling for slower-moving, but cheaper, stocks. The "Affordable Growth" strategy aims to straddle that line, seeking out companies that deliver strong earnings and revenue expansion while still trading at reasonable, not excessive, prices. This approach, sometimes called Growth at a Reasonable Price (GARP), uses a disciplined checklist: a minimum growth rating, decent profitability and financial health scores, and a valuation rating that confirms the stock isn't overheated. The goal is to capture the upside of a growing business without paying a premium that could weigh on future returns.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics, with approved products like AMVUTTRA and ONPATTRO for rare diseases. When screened through the Affordable Growth lens, ALNY presents a strong case based on its fundamental report.
Growth Engine at Full Throttle
The most impressive aspect of ALNY’s profile is its growth trajectory. The company earns a ChartMill Growth rating of 8 out of 10, driven by explosive past and expected future performance. Over the last year, earnings per share (EPS) surged by an astounding 288.04% , while revenue grew by 82.57% . Looking ahead, analysts project an average annual EPS growth of 61.72% and revenue growth of 25.57% over the coming years. This kind of momentum is rare and forms the bedrock of any GARP strategy—the engine must be strong.
Valuation: The Reasonable Price Component
For a company growing at such a rapid clip, the valuation metrics are surprisingly grounded. The ChartMill Valuation rating comes in at 6 out of 10, which is notably above the threshold for affordable growth. While the trailing Price/Earnings (P/E) ratio of 79.59 looks elevated on its own, context is crucial. Compared to its Biotechnology industry peers, ALNY is actually cheaper than 90.63% of them based on the P/E ratio. More importantly, the Price/Forward Earnings ratio drops to a far more palatable 28.04, and the Enterprise Value to EBITDA ratio shows ALNY is cheaper than 90.82% of its industry. These multiples are significantly more reasonable when factoring in the strong growth, and the low PEG Ratio explicitly confirms that the price is compensating for the expected expansion. This is the core of the Affordable Growth thesis: paying a fair price for a high-growth business.
Profitability and Health: The Supporting Pillars
An affordable growth stock should not be a ticking time bomb. The strategy requires decent profitability and financial health to ensure the growth is sustainable. Alnylam scores a 6 on Profitability and a 5 on Health, both of which meet the screen’s criteria.
Analyst and Strategy Alignment
Putting it all together, the fundamental report available here summarizes ALNY as having "excellent growth while it is valued at reasonable prices." It notes the stock as "very considerable for growth investing." This aligns perfectly with the Affordable Growth screen’s objective. The strong growth provides upside potential, while the reasonable valuation relative to its industry and future earnings helps reduce the risk of overpaying. The decent profitability and health ratings provide a floor, suggesting the business is stable enough to support its expansion plans.
Investors looking to find similar candidates that combine strong growth with fair valuations can explore the full list of results from the screen. For more opportunities, check out the Affordable Growth stock screener results to see how other stocks compare.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance and projections are not guarantees of future results.
Read full article here »